» Articles » PMID: 20930868

Management of Overactive Bladder

Overview
Journal Nat Rev Urol
Specialty Urology
Date 2010 Oct 9
PMID 20930868
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Many people are affected by urinary urgency, which can be highly bothersome. Urgency is the cornerstone symptom of overactive bladder (OAB), commonly occurring in conjunction with urinary frequency and nocturia. Once other medical causes of similar symptoms have been excluded, first-line OAB management comprises fluid intake advice and bladder training, supplemented by antimuscarinic drugs if necessary. Urodynamic confirmation of the diagnosis is required for OAB patients whose symptoms are refractory to first-line interventions. If patients are severely bothered by OAB despite optimization of medical treatment, they may proceed to invasive treatments, including neuromodulation, enterocystoplasty, detrusor myectomy, or urinary diversion. Our burgeoning understanding of the complex cellular, neural and integrative physiology of the bladder offers new insights into the causative mechanisms of OAB, and reasons why patients sometimes fail to respond to treatment. Study of sensory information pathways in the lower urinary tract has led to identification of the urothelium, afferent nerves and interstitial cells as key cellular elements in OAB. In-depth knowledge of the hierarchy of central nervous system control is lacking, but functional imaging is beginning to elucidate the challenges that lie ahead. New treatments under investigation include botulinum neurotoxin-A injection, oral β(3)-adrenergic agonists, and novel modalities for nerve stimulation. The subjective nature of urinary urgency, the lack of animal models and the multifactorial pathophysiology of OAB present significant challenges to effective clinical management.

Citing Articles

Real-time prediction of bladder urine leakage using fuzzy inference system and dual Kalman filtering in cats.

Qasemi A, Aminian A, Erfanian A Sci Rep. 2024; 14(1):3879.

PMID: 38365925 PMC: 10873426. DOI: 10.1038/s41598-024-53629-5.


Mediterranean Diet and Overactive Bladder.

Bozkurt Y, Temeltas G, Muezzinoglu T, Ucer O Int Neurourol J. 2022; 26(2):129-134.

PMID: 35793991 PMC: 9260324. DOI: 10.5213/inj.2142118.059.


A general framework for automatic closed-loop control of bladder voiding induced by intraspinal microstimulation in rats.

Yousefpour A, Erfanian A Sci Rep. 2021; 11(1):3424.

PMID: 33564019 PMC: 7873267. DOI: 10.1038/s41598-021-82933-7.


Comprehensive Review of Effective Application of Questionnaires for Clinical Research on Lower Urinary Tract Symptoms With Translation and Cultural Adaptation to the Korean Language.

Suh J, Oh S, Cho S Int Neurourol J. 2021; 24(4):313-323.

PMID: 33401352 PMC: 7788330. DOI: 10.5213/inj.2040074.037.


A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.

Wrobel A, Szopa A, Serefko A, Poleszak E Molecules. 2020; 25(6).

PMID: 32197469 PMC: 7144400. DOI: 10.3390/molecules25061384.


References
1.
Drake M . The integrative physiology of the bladder. Ann R Coll Surg Engl. 2008; 89(6):580-5. PMC: 2121225. DOI: 10.1308/003588407X205585. View

2.
Shaban A, Drake M . Botulinum toxin treatment for overactive bladder: risk of urinary retention. Curr Urol Rep. 2008; 9(6):445-51. DOI: 10.1007/s11934-008-0077-1. View

3.
Chung S, Chiu B, Kuo H, Chuang Y, Wang C, Guan Z . Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int. 2009; 105(5):668-72. DOI: 10.1111/j.1464-410X.2009.08927.x. View

4.
Kuo H, Liu H, Chancellor M . Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn. 2009; 29(3):482-7. DOI: 10.1002/nau.20741. View

5.
de Groat W . A neurologic basis for the overactive bladder. Urology. 1998; 50(6A Suppl):36-52; discussion 53-6. DOI: 10.1016/s0090-4295(97)00587-6. View